Surgical Robotics Technology

Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System ASTRO 2023


Accuray Incorporated announced that the company has a 510(k) pending for an online adaptive therapy option*, Cenos™, for its Radixact® System. The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO (American Society for Radiation Oncology) Annual Meeting in San Diego, California, October 1-4, 2023. Cenos is designed to enable medical care teams to quickly and efficiently make adjustments, if necessary, to a treatment plan while the patient is still on the treatment table.

Over the course of radiation treatments the size, shape or location of tumors may change and their proximity to organs and other healthy tissue may shift as patients gain or lose weight. Accuray customers are currently able to leverage real-time adaptive therapy through the company’s proprietary Synchrony® technology and offline adaptive with PreciseART® radiotherapy to account for some of the anatomical changes that occur during radiation delivery. With the addition of Cenos, Accuray customers will have the ability to perform online adaptation of their treatment plan to account for changes that may occur between treatment sessions. Accuray is committed to offering the most comprehensive adaptive tool set to  provide care teams with choices and the flexibility to optimize and streamline the workflow for each patient, helping to ensure clinical objectives are met.

One of the most important steps in the planning process is contouring – defining the border of the tumor and organs at risk – yet it is extremely labor and time intensive. Automating the contouring portion of the planning process using tools such as the one developed by Limbus AI will make it practical for radiotherapy clinics of all sizes to adopt online adaptive therapy, when needed.

“We’re proud of the work we’re doing with Limbus and our achievements to date. The goal of Cenos is to provide our customers with a comprehensive and efficient approach to adaptive radiotherapy that includes a solution for making online adaptive therapy feasible for any interested Radixact customer,” said Suzanne Winter, President and CEO of Accuray. “We are committed to continuing to evolve our radiation delivery systems to facilitate more personalized care for more cancer patients. Approximately 50% of all cancer patients will need treatment with radiotherapy[1], making it critical that we do everything possible to help ensure that clinicians have the tools to optimize treatments.”

“We’re very happy to be partnering with Accuray,” said Dr Karl Otto, CEO of Limbus AI. “Our AI based technology, Limbus Contour, has seen rapid adoption by over 250 clinics globally. Embedding it into the Cenos online adaptive solution will help provide for accurate and fast contouring essential to real-world clinical implementation of adaptive treatment.”

Additional Accuray Highlights at the ASTRO meeting Include:

  • Accuray Financial Services – new: The increasing use of Accuray radiation delivery systems is a reflection of their precision and accuracy, and enhancements introduced in the areas of image quality, speed, versatility, and workflow efficiencies. In the U.S. market Accuray is making it easier for customers to obtain the company’s advanced hardware and software or to keep their technology up to date through flexible financing options.
  • Alliance A+ – new: A curated support solutions portfolio covering multiple functions including service, clinical applications and physics, designed to augment medical care team resources and optimize their practice.
  • VitalHold™** Breast Package for the Radixact® System – now 510(k) cleared and obtained CE mark in the EU marketVitalHold enables deep inspiration breath hold (DIBH) treatments on the Radixact System through a fully integrated and automated surface-guided radiotherapy (SGRT) solution. The Radixact System offers compromise-free capabilities to treat the full spectrum of breast cases in as little as two minutes, leveraging both TomoHelical™ (helical delivery) and TomoDirect™ (tangential beams).
  • CyberKnife® System: The CyberKnife S7™ System combines speed, advanced precision, and real-time (AI)-driven motion tracking and synchronization treatment delivery, using Synchrony®, for all stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments.

*Cenos is 510(k) pending. The solution is not available for sale in the USA. It is not CE marked and availability is subject to regulatory clearance or approval in some markets.
**VitalHold™ availability is subject to regulatory clearance or approval in some markets.

1 Atun R. et al. Lancet Oncol 2015; 16: 1153–86

Source: Accuray Incorporated

Surgical Robotics Technology

Join thousands of Surgical Robotics Experts and get the latest updates straight to your inbox!